Compare First Citizens BancShares Inc (FCNCA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? First Citizens BancShares Inc trades at $2,052.8 (market cap $23.01B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: First Citizens BancShares Inc is far larger — about 23.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 30 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FCNCA | MRVI | |
|---|---|---|
Market Cap | $23.01B | $972.90M |
Volume | 64,069 | 4,325,710 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $9.00 |
52-Week Low | $1.64K | $2.83 |
Typical Hold Time | 30 Days | 0 Days |
Dividend Yield | 0.4% | — |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCNCA trades at $2,075.12, down 0.35% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $57.09 per share, beating estimates, and maintains a net income margin of 25.23%. Recent news includes a $157 million financing deal and branch expansion initiatives, signaling growth. Cash flow improved to a net positive $630 million in 2026 from a slight deficit in 2025.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but technical bearishness and high institutional hold ratings suggest near-term caution. Key risks include execution of expansion and interest rate sensitivity. The stock offers value with a P/E of 11.13, yet requires monitoring of technical levels for entry.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
